The CPT1A inhibitor etomoxir can affect and coordinate with the conventional chemotherapy drug cisplatin to increase tumor cell sensitivity to the chemotherapeutic agent, inhibit tumor cell proliferation and promote apoptosis, thus providing a novel approach to improving the efficacy of chemotherapy in non-small cell lung cancer (Dheeraj et al., 2018; Hoy et al., 2021). Here, CPT1A is linked to neoplasm.